Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
Investors are racing to buy TrovaGene Inc (NASDAQ:TROV) shares after the U.S.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced the successful completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, …
BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.
ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
Drug maker Omeros Corporation (NASDAQ:OMER) announced that it entered into a settlement agreement with Par Pharmaceutical and its subsidiary Par Sterile Products, resolving …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
Investors are pricing in some optimism in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), after the drug maker announced that the FDA has granted Breakthrough Therapy Designation to …
